These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29911403)

  • 41. Ertugliflozin for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):70-72. PubMed ID: 29667948
    [No Abstract]   [Full Text] [Related]  

  • 42. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.
    Dawra VK; Liang Y; Shi H; Bass A; Hickman A; Terra SG; Zhou S; Cutler D; Sahasrabudhe V
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):207-216. PubMed ID: 30802200
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview.
    Dash RP; Babu RJ; Srinivas NR
    Xenobiotica; 2017 Nov; 47(11):1015-1026. PubMed ID: 27718782
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.
    Raje S; Callegari E; Sahasrabudhe V; Vaz A; Shi H; Fluhler E; Woolf EJ; Schildknegt K; Matschke K; Alvey C; Zhou S; Papadopoulos D; Fountaine R; Saur D; Terra SG; Stevens L; Gaunt D; Cutler DL
    Clin Transl Sci; 2018 Jul; 11(4):405-411. PubMed ID: 29575530
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Company stock prices before and after public announcements related to oncology drugs.
    Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
    J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outsourcing bioanalytical services at Janssen Research and Development: the sequel anno 2017.
    Dillen L; Verhaeghe T
    Bioanalysis; 2017 Aug; 9(15):1195-1201. PubMed ID: 28762758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An analysis of the clinical development of drugs in Norway for the years 2000 and 2004: the influence of the pharmaceutical industry.
    Winther FO; Hole OP; Nitter-Hauge S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):909-12. PubMed ID: 17673994
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
    Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
    Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The coming commoditization of processes.
    Davenport TH
    Harv Bus Rev; 2005 Jun; 83(6):100-8, 149. PubMed ID: 15942994
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MRD to help assess response in CLL.
    Romero D
    Nat Rev Clin Oncol; 2019 Feb; 16(2):68. PubMed ID: 30573789
    [No Abstract]   [Full Text] [Related]  

  • 52. Zatosetron. LY 191617, LY 277359.
    Drugs R D; 1999 Oct; 2(4):253-5. PubMed ID: 10659404
    [No Abstract]   [Full Text] [Related]  

  • 53. Assessing Study Start-up Practices, Performance, and Perceptions Among Sponsors and Contract Research Organizations.
    Lamberti MJ; Wilkinson M; Harper B; Morgan C; Getz K
    Ther Innov Regul Sci; 2018 Sep; 52(5):572-578. PubMed ID: 29714558
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral care clinical trials at Hill Top Research.
    Mason S
    J Am Coll Dent; 2001; 68(4):24-8. PubMed ID: 11887364
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Compliance revisited: pharmaceutical drug trials in the era of the contract research organization.
    Jonvallen P
    Nurs Inq; 2009 Dec; 16(4):347-54. PubMed ID: 19906285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Continuous quality improvement in contract research organizations--the customer focus.
    Sollecito WA; Kaluzny AD
    Qual Manag Health Care; 1999; 7(3):7-21. PubMed ID: 10537463
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Interim analyses].
    Kramar A; Paoletti X
    Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outsourcing lead optimisation--the quiet revolution.
    Clark DE; Newton CG
    Drug Discov Today; 2004 Jun; 9(11):492-500. PubMed ID: 15149625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
    Anderson JR; Krailo M
    Am J Bioeth; 2011 Mar; 11(3):18-9. PubMed ID: 21400379
    [No Abstract]   [Full Text] [Related]  

  • 60. Kinase inhibitors overachieve in CLL.
    Garber K
    Nat Rev Drug Discov; 2014 Mar; 13(3):162-4. PubMed ID: 24549135
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.